Skip to main content
News

Distressed Asset Acquisition Opportunities for Biopharma Companies

February 6, 2024
Arnold & Porter Webinar
A significant number of biopharmaceutical companies have recently filed for bankruptcy, often seeking to sell assets through the bankruptcy process, including via section 363 sales. Such bankruptcies can present significant opportunities for biopharma companies. Join Ben Mintz, Rosa Evergreen, and Eric Rothman, partners at Arnold & Porter, as they discuss the key features, timeline, process, and pros and cons of asset acquisitions in bankruptcy cases.

Meet the Speakers

Benjamin Mintz
Partner
Arnold & Porter
Rosa J. Evergreen
Partner
Arnold & Porter
Eric Rothman
Partner
Arnold & Porter